Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Cidara Therpeutics

6 Posts
| Omlaag ↓
  1. R dayhigh 14 december 2021 16:59
    resultaten. zojuist speculatief plukje aangekocht, . lijkt me wat overdreven deze 25% afstraffing . op de plank

    Cidara Therapeutics, Mundipharma Say Fungal Infections Treatment Met Primary Goals in Late-Stage Trial
    BY MT Newswires
    — 8:02 AM ET 12/14/2021
    08:02 AM EST, 12/14/2021 (MT Newswires) -- Cidara Therapeutics ( CDTX
    ) and Mundipharma said Tuesday a phase 3 trial of rezafungin met its primary endpoints as a treatment for fungal infections versus standard of care, paving the way for global regulatory filings in mid-2022.

    Rezafungin met the primary endpoint for the U.S. Food and Drug Administration New Drug Application submission of all-cause mortality at day 30, and also met the primary endpoint for the European Medicines Agency Marketing Authorization Application submission of global cure at day 14.

    Both results demonstrated statistical non-inferiority of rezafungin dosed once-weekly, versus caspofungin dosed once-daily, the current standard of care.

    Rezafungin was generally well tolerated and had a similar safety profile to caspofungin.

    "With the results of both the STRIVE and ReSTORE trials now in hand, which together form our registration package, we intend to file our NDA with the FDA and other regulators outside the US, in mid-2022," said a principal investigator in the ReSTORE trial, George Thompson.

    Cidara Therapeutics ( CDTX
    ) and Mundipharma are co-developing rezafungin under a partnership agreement.

    Cidara shares were down nearly 4%.

    Price: 1.66, Change: +0.03, Percent Change: +1.84
  2. R dayhigh 17 december 2021 10:56
    Onderhand alweer opgeveerd naar 1,39.

    H.C. Wainwright Thinks Cidara Therapeutics’ Stock is Going to Recover

    H.C. Wainwright analyst Ed Arce maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) today and set a price target of $7.50. The company’s shares closed last Tuesday at $1.18, close to its 52-week low of $1.10.

    According to, Arce is a 5-star analyst with an average return of 15.4% and a 39.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals.

    The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cidara Therapeutics with a $6.55 average price target, representing a 372.9% upside. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $6.00 price target.

    The company has a one-year high of $3.15 and a one-year low of $1.10. Currently, Cidara Therapeutics has an average volume of 744K.

    Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDTX in relation to earlier this year.

6 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum


AEX 730,09 -0,22%
EUR/USD 1,0651 0,00%
FTSE 100 7.683,91 +0,07%
Germany40^ 15.500,70 -0,46%
Gold spot 1.925,23 0,00%
NY-Nasdaq Composite 13.211,81 -0,09%




ASR Ne...

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links